Investigating the use and costs of targeted oral cancer medications
Targeted Oral Anticancer Agents: Patterns of Indicated and Off-Label Use, the Associated Factors and Economic Implications
This study is looking at how cancer patients use new oral medications designed to help them live longer, focusing on how well these treatments work, their costs, and how often patients stick with them, so we can better understand if these medicines are easy to get and affordable for everyone.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-11034631 on NIH RePORTER |
What this research studies
This research focuses on targeted oral anticancer medications (TOAMs) that have been developed to improve survival rates in cancer patients. It aims to understand how these medications are used, both as prescribed and off-label, and to analyze the economic implications of their use, including costs and patient adherence. By examining data from large claims databases, the study will explore factors influencing treatment initiation and patterns of medication discontinuation among cancer patients. The findings could provide insights into the accessibility and affordability of these treatments for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research include cancer patients who are prescribed targeted oral anticancer medications.
Not a fit: Patients who are not receiving targeted oral anticancer medications or those with conditions not treated by these agents may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved understanding of how to make targeted cancer treatments more accessible and affordable for patients.
How similar studies have performed: Previous research has shown success in understanding medication adherence and economic implications in cancer treatment, suggesting that this approach could yield valuable insights.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Shih, Ya-Chen Tina — University of California Los Angeles
- Study coordinator: Shih, Ya-Chen Tina
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.